Model Informed Drug Development Archives

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

Webinar

Leveraging the full potential of PBPK models to accelerate drug development

CertaraJanuary 30, 2026

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

CertaraJanuary 26, 2026

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CertaraJanuary 22, 2026

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

CertaraJanuary 14, 2026

Webinar

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

CertaraJanuary 14, 2026

Webinar

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

CertaraJanuary 13, 2026

Publication

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…

CertaraJanuary 7, 2026

Blog

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

CertaraDecember 29, 2025

Model Informed Drug Development

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Leveraging the full potential of PBPK models to accelerate drug development

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Newsletter sign up

Quick links

Solutions

Contact